The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression

Leukemia

Volumn 27, Issue 4, 2013, Pages 961-964

  Azab, A K ^a   Weisberg, E ^b   Sahin, I ^b   Liu, F ^c   Awwad, R ^b   Azab, F ^a   Liu, Q ^c   Griffin, J D ^b   Ghobrial, I M ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; IMATINIB; NILOTINIB; UVOMORULIN;

CANCER GROWTH; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL; HYPOXIA; LETTER; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CADHERINS; CELL HYPOXIA; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; RECEPTORS, CXCR4;

EID: 84876159957     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.353     Document Type: Letter

References (15)

1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
2. Wertheim JA, Perera SA, Hammer DA, Ren R, Boettiger D, Pear WS. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood 2003; 102: 2220-2228.
3. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001; 1551: M11-M18.
4. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
5. Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012a; 21: 577-592.
6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
7. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCRABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748-755.
8. Jin L, Tabe Y, Konoplev S, Xu Y, Levsath CE, Lu H et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7: 48-58.
9. Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dosedependent manner resulting in increased susceptibility of BCR-ABL\+ cell to Imatinib and Nilotinib. Leuk Lymphoma 2009; 50: 1676-1686.
10. Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006; 20: 1291-1293.
11. Zhang H, Li H, Xi HS, Li S. HIF1a is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 2012b; 119: 2595-2607.
12. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006; 5: 3113-3121.
13. Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012; 26: 985-990.
14. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
15. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012; 119: 5782-5794.